Literatur
Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M et al (2011) Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 17:952–960
Zhao Y, Liu L, Huang J, Shi S, Lv J, Liu G, Zhao M, Zhang H (2015) Plasma soluble urokinase receptor level is correlated with podocytes damage in patients with IgA nephropathy. PLOS One 10:e0132869
Theilade S, Lyngbaek S, Hansen TW, Eugen-Olsen J, Fenger M, Rossing P, Jeppesen JL (2015) Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med 277:362–371
Meijers BK, Reiser J (2014) Reassessing the reassessment of suPAR in glomerular disease. Front Med (Lausanne) 1:59
Spinale JM, Mariani LH, Kapoor S, Zhang J, Weyant R, Song PX, Wong HN, Troost JP, Gadegbeku CA, Gipson DS et al (2015) A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87:564–574
Meijers B, Poesen R, Claes K, Dietrich R, Bammens B, Sprangers B, Naesens M, Storr M, Kuypers D, Evenepoel P (2015) Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int 87:210–216
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
J. Lutz gibt an, dass kein Interessenkonflikt besteht.
Additional information
Redaktion
T. Feldkamp, Kiel
J. Lutz, Mainz
L. T. Weber, Köln
Rights and permissions
About this article
Cite this article
Lutz, J. Ist suPAR ein Marker für chronische Niereninsuffizienz?. Nephrologe 11, 148–149 (2016). https://doi.org/10.1007/s11560-015-0044-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11560-015-0044-z